| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
1-Piperidineacetamide, N-[6-[(3,4-dihydro-2-phenyl-2H-1-benzopyran-6-yl)oxy]-3-pyridinyl]-4-hydroxy- manufacturers
- ORM-10962
-
- $2500.00
-
2026-04-22
- CAS:763926-98-3
- Purity:
- Supply Ability: 10g
- ORM-10962
-
- $2500.00
-
2025-08-22
- CAS:763926-98-3
- Purity:
- Supply Ability: 10g
|
| | 1-Piperidineacetamide, N-[6-[(3,4-dihydro-2-phenyl-2H-1-benzopyran-6-yl)oxy]-3-pyridinyl]-4-hydroxy- Basic information |
| | 1-Piperidineacetamide, N-[6-[(3,4-dihydro-2-phenyl-2H-1-benzopyran-6-yl)oxy]-3-pyridinyl]-4-hydroxy- Chemical Properties |
| Boiling point | 704.2±60.0 °C(Predicted) | | density | 1.280±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO: 250 mg/mL (544.02 mM) | | form | Solid | | pka | 13.14±0.70(Predicted) | | color | Light yellow to yellow |
| | 1-Piperidineacetamide, N-[6-[(3,4-dihydro-2-phenyl-2H-1-benzopyran-6-yl)oxy]-3-pyridinyl]-4-hydroxy- Usage And Synthesis |
| Uses | ORM-10962 can be synthesized from 6-Hydroxyflavanone (H942412), a flavonoid/universal plant pigment. | | in vivo | ORM-10962 (0.3 mg/kg, IV, once) pre-treatment significantly delays the development and recurrence of ventricular extrasystoles (by about 50%) or ventricular tachycardia (by about 30%) in anesthetized guinea pigs[1]. | Animal Model: | Male guinea-pigs (250-300 g)[1] | | Dosage: | 0.3 mg/kg | | Administration: | IV, 10 min before starting ouabain infusion | | Result: | Significantly delayed the development of ventricular extrasystoles (from 24±1.7 min in controls to 36.6±2.7 min in the presence of the drug) or ventricular tachycardia (from 31.8±1.8 min in controls to 40.8±2.1 min in the presence of the drug). |
|
| | 1-Piperidineacetamide, N-[6-[(3,4-dihydro-2-phenyl-2H-1-benzopyran-6-yl)oxy]-3-pyridinyl]-4-hydroxy- Preparation Products And Raw materials |
|